skip to Main Content
Contact Us   480.314.3070 |

New Frontiers in Oncology Imaging

The fusion of new therapeutics, imaging, and biomarker development is directing us into an advanced realm of healthcare delivery. With these exciting new technologies comes a responsibility to accurately and precisely measure their effects. Each and every data point counts and is critical for successful trial completion, from Phase 0/I through Phase III and FDA submission.

At Imaging Endpoints, our scientific and radiologic capabilities help assure the appropriate use of imaging technology while preserving the integrity of your clinical trial. Our organization is unique in that we have 100+ physician readers comprised of 40 in-house radiologists, globally recognized expert clinical trial radiologists, oncologists, surgeons and other U.S. based medical specialists and scientists.

We are one of the largest global imaging CROS in oncology and our team of project managers and board-certified, fellowship-trained radiologists and nuclear medicine physicians have been successfully involved in hundreds of early and late-stage oncology trials across virtually every disease type, criterion and criterion modification.

Assessments

Advanced Analysis

  • Radiomic Analyses
    • Link imaging with omics for non-invasive determination of omics on every lesion
  • Quantitative Textural AnalysisTM (TexRAD)
    • Quantitate biology of response (i.e. heterogeneity, perfusion, hypoxia, etc.)
  • Pseudo progression analysis
  • Macrophage Analysis
  • Hypoxia
  • Total-body metabolic tumor volume
  • CNS tumor blood volumes
  • Automated quantitation of metastatic tumor burden on bone scans
  • PET agents for immune trafficking and receptor imaging, CD8 imaging
  • Dynamic PET for biodistribution
  • Radiolabeled binding
  • SPECT imaging for cancer detection and treatment response

Biometric Discovery

  • Prediction of immune response
  • Kras mutations
  • Alk rearrangements
  • ER/PR, proliferation
  • Early detection
  • EMT
  • Prognostic signatures in solid tumors
  • Fat content and sarcopenia
  • Pseudo-progression
  • Hallmarks of cancer

Functional

  • Perfusion measurements (PET, DCE-MRI and CT)
  • Metabolic and proliferation (PET/CT – FDG, 11C-methionine & FLT, 18F-Axumin,
    18F-FES, 68Ga-PSMA-11, 68Ga-DOTA,)
  • Tumor Hypoxia (F-MISO)
  • Immune system imaging (89Zr-CD8 PET)
  • Tumor associated macrophage imaging
  • Fat and fibrosis analysis
  • pH imaging with CEST-MRI

Semi-Quantitative

  • RECIST (1.0, 1.1), mRECIST
  • iRECIST, itRECIST, irRECIST, irRC
  • WHO criteria
  • PERCIST and EORTC criteria for PET response
  • CHOI criteria for response to tumors
  • Macdonald, RANO, iRANO, mRANO and RAPNO for Neuro-Oncology
  • PCWG3 criteria for Prostate cancer
  • Cheson, Lugano and RECIL for lymphoma;
  • Olsen criteria; IWCLL for CLL; MDA for bone metastases
  • Pseudo progression measurements

Quantitative

  • Tumor volume – based on CT, MRI
  • Tumor metabolic volume and Tumor lesion glycolysis (PET/CT)
  • Tumor density
  • Tumor kinetics
  • Tumor heterogeneity with QTA
  • Bone metastasis burden on Bone Scans

Modalities

  • PET/CT and SPECT/CT – multiple radiopharmaceuticals
  • MRI – DCE, ADC, anatomical, spectroscopy
  • CT – Perfusion, anatomical
  • Breast-based imaging modalities: MRI, digital mammography,
    ultrasound, tomosynthesis
  • US
  • Angiography
  • X-ray, Planar Nuclear Medicine (Bone Scans, etc)

Immune Therapy and Immune System Imaging

  • Cellular therapy with over active trials in hematology and solid tumors
  • Viral therapy in neuro oncology and systemic disease
  • Intra tumoral injection and vaccines
  • CPI therapy
  • Rational combinations include ablative therapy, radiation therapy and novel immune system stimulators
  • PET/SPECT immune imaging agents and radiomic signatures
  • Immune mediated inflammatory disease
Back To Top